Focused On-demand Library for Large ribosomal subunit protein uL30m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TCC3

UPID:

RM30_HUMAN

Alternative names:

39S ribosomal protein L28, mitochondrial; 39S ribosomal protein L30, mitochondrial

Alternative UPACC:

Q8TCC3; A6NIC6; D3DVI0; D3DVI3; Q0D2Q7; Q6ZTP4; Q96Q69; Q9P0N0

Background:

The Large ribosomal subunit protein uL30m, also known as 39S ribosomal protein L28 and L30, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the 39S large ribosomal subunit and is involved in protein synthesis within mitochondria. The protein's alternative names highlight its significance in the mitochondrial ribosomal complex, underscoring its essential function in cellular energy production and metabolic processes.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein uL30m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it an intriguing target for research aimed at addressing mitochondrial disorders and diseases linked to mitochondrial dysfunction.